170 related articles for article (PubMed ID: 25659771)
21. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
22. 2-(4-Methylsulfonylaminophenyl) propanamide TRPV1 antagonists: Structure-activity relationships in the B and C-regions.
Sun W; Liu K; Ryu H; Kang DW; Kim YS; Kim MS; Cho Y; Bhondwe RS; Thorat SA; Kim HS; Pearce LV; Pavlyukovets VA; Tran R; Morgan MA; Lazar J; Ryder CB; Toth A; Blumberg PM; Lee J
Bioorg Med Chem; 2012 Feb; 20(3):1310-8. PubMed ID: 22227463
[TBL] [Abstract][Full Text] [Related]
23. N-4-t-Butylbenzyl 2-(4-methylsulfonylaminophenyl) propanamide TRPV1 antagonists: Structure-activity relationships in the A-region.
Kim YS; Kil MJ; Kang SU; Ryu H; Kim MS; Cho Y; Bhondwe RS; Thorat SA; Sun W; Liu K; Lee JH; Choi S; Pearce LV; Pavlyukovets VA; Morgan MA; Tran R; Lazar J; Blumberg PM; Lee J
Bioorg Med Chem; 2012 Jan; 20(1):215-24. PubMed ID: 22169633
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of N
Gao M; Nie C; Li J; Song B; Cheng X; Sun E; Yan L; Qian H
Bioorg Chem; 2019 Feb; 82():100-108. PubMed ID: 30278281
[TBL] [Abstract][Full Text] [Related]
25. Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.
Liao C; Liu Y; Liu C; Zhou J; Li H; Wang N; Li J; Liu T; Ghaleb H; Huang W; Qian H
Bioorg Med Chem; 2018 Feb; 26(4):845-854. PubMed ID: 29317149
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole triazole derivatives as potent TRPV1 antagonists.
Li J; Nie C; Qiao Y; Hu J; Li Q; Wang Q; Pu X; Yan L; Qian H
Eur J Med Chem; 2019 Sep; 178():433-445. PubMed ID: 31202991
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of benzamide derivatives as TRPV1 antagonists.
Shishido Y; Jinno M; Ikeda T; Ito F; Sudo M; Makita N; Ohta A; Iki-Taki A; Ohmi T; Kanai Y; Tamura T; Shimojo M
Bioorg Med Chem Lett; 2008 Feb; 18(3):1072-8. PubMed ID: 18155908
[TBL] [Abstract][Full Text] [Related]
28. α-Substituted 2-(3-fluoro-4-methylsulfonamidophenyl)acetamides as potent TRPV1 antagonists.
Tran PT; Kim HS; Ann J; Kim SE; Kim C; Hong M; Hoang VH; Ngo VT; Hong S; Cui M; Choi S; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Stockhausen H; Christoph T; Lee J
Bioorg Med Chem Lett; 2015 Jun; 25(11):2326-30. PubMed ID: 25937016
[TBL] [Abstract][Full Text] [Related]
29. N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor.
Lee J; Lee J; Kang M; Shin M; Kim JM; Kang SU; Lim JO; Choi HK; Suh YG; Park HG; Oh U; Kim HD; Park YH; Ha HJ; Kim YH; Toth A; Wang Y; Tran R; Pearce LV; Lundberg DJ; Blumberg PM
J Med Chem; 2003 Jul; 46(14):3116-26. PubMed ID: 12825950
[TBL] [Abstract][Full Text] [Related]
30. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
[TBL] [Abstract][Full Text] [Related]
31. Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide.
Nie C; Li Q; Qiao Y; Hu J; Gao M; Wang Y; Qiao Z; Wang Q; Yan L; Qian H
Eur J Med Chem; 2020 May; 194():112236. PubMed ID: 32217416
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
[TBL] [Abstract][Full Text] [Related]
33. Structure-activity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxamide (V116517) as a clinical candidate for pain management.
Tafesse L; Kanemasa T; Kurose N; Yu J; Asaki T; Wu G; Iwamoto Y; Yamaguchi Y; Ni C; Engel J; Tsuno N; Patel A; Zhou X; Shintani T; Brown K; Hasegawa T; Shet M; Iso Y; Kato A; Kyle DJ
J Med Chem; 2014 Aug; 57(15):6781-94. PubMed ID: 25057800
[TBL] [Abstract][Full Text] [Related]
34. Stereospecific high-affinity TRPV1 antagonists: chiral N-(2-benzyl-3-pivaloyloxypropyl) 2-[4-(methylsulfonylamino)phenyl]propionamide analogues.
Ryu H; Jin MK; Kim SY; Choi HK; Kang SU; Kang DW; Lee J; Pearce LV; Pavlyukovets VA; Morgan MA; Tran R; Toth A; Lundberg DJ; Blumberg PM
J Med Chem; 2008 Jan; 51(1):57-67. PubMed ID: 18072720
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
[TBL] [Abstract][Full Text] [Related]
36. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
[TBL] [Abstract][Full Text] [Related]
37. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
[TBL] [Abstract][Full Text] [Related]
38. N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1).
Jetter MC; McNally JJ; Youngman MA; McDonnell ME; Dubin AE; Nasser N; Zhang SP; Codd EE; Colburn RW; Stone DR; Brandt MR; Flores CM; Dax SL
Bioorg Med Chem Lett; 2008 Apr; 18(8):2730-4. PubMed ID: 18359227
[TBL] [Abstract][Full Text] [Related]
39. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.
Swanson DM; Dubin AE; Shah C; Nasser N; Chang L; Dax SL; Jetter M; Breitenbucher JG; Liu C; Mazur C; Lord B; Gonzales L; Hoey K; Rizzolio M; Bogenstaetter M; Codd EE; Lee DH; Zhang SP; Chaplan SR; Carruthers NI
J Med Chem; 2005 Mar; 48(6):1857-72. PubMed ID: 15771431
[TBL] [Abstract][Full Text] [Related]
40. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1.
Gavva NR; Tamir R; Klionsky L; Norman MH; Louis JC; Wild KD; Treanor JJ
Mol Pharmacol; 2005 Dec; 68(6):1524-33. PubMed ID: 16135784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
